Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Humedix","sponsor":"Kineta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humedix Closes Strategic Investment in US-based Kineta to Boost CMO Business","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by Humedix

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Humedix has secured certain exclusive distribution rights in Korea for products that are commercialized from Kineta's pipeline currently under development including KVA12.1.

            Lead Product(s): KVA12.1

            Therapeutic Area: Oncology Product Name: KVA12.1

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kineta

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 04, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY